未登录

J

Jordan R. Smith

high point university

H指数:20

被引数:1,026

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Filling the Gaps: A Review and Update on Beta-Lactamase Inhibitor Combinations

Current Infectious Disease Reports

IF2.9

2026-01-240

OAAI

Quantifying Antimicrobial Disposals at Six Community Pharmacies With Longitudinal Medication Disposal Programs: An Underappreciated Component of a One Health Approach to Antimicrobial Stewardship

量化六家实施纵向药物处置计划的社区药房中抗菌药物处置量：一种“同一健康”方法在抗菌药物管理中被忽视的组成部分

OPEN FORUM INFECTIOUS DISEASES

IF3.8

2025-10-011

OAAI

A lipoglycopeptide antibiotic for Gram-positive biofilm-related infections

SCIENCE TRANSLATIONAL MEDICINE

IF14.6

2022-09-149

PRE

Blaskovich, Mark A. T.; Hansford, Karl A.; Butler, Mark S.; Ramu, Soumya; Kavanagh, Angela M.; Jarrad, Angie M.; Prasetyoputri, Anggia; Pitt, Miranda E.; Huang, Johnny X.; Lindahl, Fredrik; Ziora, Zyta M.; Bradford, Tanya; Muldoon, Craig; Rajaratnam, Premraj; Pelingon, Ruby; Edwards, David J.; Zhang, Bing; Amado, Maite; Elliott, Alysha G.; Zuegg, Johannes; Coin, Lachlan; Woischnig, Anne-Kathrin; Khanna, Nina; Breidenstein, Elena; Stincone, Anna; Mason, Clive; Khan, Nawaz; Cho, Hye-Kyung; Karau, Melissa J.; Greenwood-Quaintance, Kerryl E.; Patel, Robin; Wootton, Mandy; James, Meagan L.; Hutton, Melanie L.; Lyras, Dena; Ogunniyi, Abiodun D.; Mahdi, Layla K.; Trott, Darren J.; Wu, Xiaoqian; Niles, Samantha; Lewis, Kim; Smith, Jordan R.; Barber, Katie E.; Yim, Juwon; Rice, Seth Alan; Rybak, Michael J.; Ishmael, Chad R.; Hori, Kellyn R.; Bernthal, Nicholas M.; Francis, Kevin P.; Roberts, Jason A.; Paterson, David L.; Cooper, Matthew A.

The Use of Long-Acting Lipoglycopeptides for the Treatment of Serious, Off-label Infections: a Review of the Literature

infectious disease reports

IF2.9

2021-10-151

PREAI

Biofilm Time-Kill Curves to Assess the Bactericidal Activity of Daptomycin Combinations against Biofilm-Producing Vancomycin-Resistant Enterococcus faecium and faecalis

ANTIBIOTICS-BASEL

IF4.6

2021-07-2312

OAAI

Impact of Daptomycin Dose Exposure Alone or in Combination with β-Lactams or Rifampin against Vancomycin-Resistant Enterococci in an In Vitro Biofilm Model

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2020-04-2122

OAAI

Evaluation of dalbavancin alone and in combination with β-lactam antibiotics against resistant phenotypes of Staphylococcus aureus

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

IF3.6

2018-09-2725

OAAI

Combination of Tedizolid and Daptomycin against Methicillin-Resistant Staphylococcus aureus in an In Vitro Model of Simulated Endocardial Vegetations

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2018-05-0119

OAAI

Evaluation of daptomycin combinations with cephalosporins or gentamicin against Streptococcus mitis group strains in an in vitro model of simulated endocardial vegetations (SEVs)

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

IF3.6

2017-05-0518

OAAI

β-Lactamase Inhibitors Enhance the Synergy between β-Lactam Antibiotics and Daptomycin against Methicillin-Resistant Staphylococcus aureus

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2017-01-0110

OAAI

Daptomycin in Combination with Ceftolozane-Tazobactam or Cefazolin against Daptomycin-Susceptible and -Nonsusceptible Staphylococcus aureus in an In Vitro, Hollow-Fiber Model

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2016-07-0119

OAAI

New Guidelines Endorse Old Recommendations for Invasive Enterococcal Infections

CLINICAL INFECTIOUS DISEASES

IF7.3

2016-05-080

OAAI

Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2016-04-0121

OAAI

Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

IF3.6

2015-10-1663

OAAI

Telavancin Demonstrates Activity against Methicillin-Resistant Staphylococcus aureus Isolates with Reduced Susceptibility to Vancomycin, Daptomycin, and Linezolid in Broth Microdilution MIC and One-Compartment Pharmacokinetic/Pharmacodynamic Models

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2015-09-0120

OAAI

Evaluation of Ceftaroline Alone and in Combination against Biofilm-Producing Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Daptomycin and Vancomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2015-08-0146

OAAI

β-Lactams Enhance Daptomycin Activity against Vancomycin-Resistant Enterococcus faecalis and Enterococcus faecium in In Vitro Pharmacokinetic/Pharmacodynamic Models

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2015-05-0141

OAAI

Impact of the Combination of Daptomycin and Trimethoprim-Sulfamethoxazole on Clinical Outcomes in Methicillin-Resistant Staphylococcus aureus Infections

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2015-04-0125

OAAI

β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium

Β-内酰胺与达托霉素的组合对耐万古霉素的粪肠球菌和屎肠球菌具有协同作用

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

IF3.6

2015-02-01101

OAAI

High-Dose Daptomycin Therapy for Staphylococcal Endocarditis and When to Apply It

infectious disease reports

IF2.9

2014-08-2826

OAAI